Advance the use of and access to FDA-approved medications to treat addiction and mental illness in criminal justice and public health settings; pharmaceutical supply chain issues; drug pricing.
Implementation of Comprehensive Addiction and Recovery Act of 2016 (P.L.114-198), 21st Century Cures Act (P.L.114-255), SUPPORT for Patients and Communities Act (P.L.115-271), and CARES Act (P.L.116-136).
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Drug Pricing; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Resolution (S.Con.Res.14)/Budget Reconciliation (H.R.5376).
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings, including SAMHSA funding;
FY2022 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (H.R.4355/S.2604);
FY2022 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.4505);
FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502);
FY2022 Department of the Interior, Environment, and Related Agencies Appropriations Act (H.R.4372);
H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation;
FY2022 Consolidated Appropriations Act (H.R.4502).
Issues related to pharmaceutical IP and supply chain.
Duration: October 8, 2015
to
November 8, 2021
General Issues: Health Issues , Medicare/Medicaid , Budget/Appropriations , Trade (Domestic & Foreign) , Alcohol & Drug Abuse , Taxation/Internal Revenue Code
Spending: about $1,330,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2015: U.S. Senate, House of Representatives, Executive Office of the President (EOP), Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
John Green Dep Chief of Staff/Leg Aide, Senator Trent Lott
Stewart Hall Legislative Director, Senator Richard Shelby
Todd M. Weiss SrPolAdv,Hutchinson;LA/LD,Santorum;Staff,HouseIntlRelComm
Hunter Moorhead Adv,Cochran;NatlEcoCoun;SenAppro;LACochran;HRAg;LAParker
Matt Wise LegDirector/LegAide, Rep.Mary Fallin; LC, Sen.Conrad Burns
Steve Tilton HCRPolCoor/SenPolAdvr:ENG/CommBilirakis
Anne W. Brady Deputy Chief of Staff, Rep. Mark Schauer
Jake Perry Legislative Aide, Sen. Harry Reid
Elizabeth Hart CoS,Cong. John Carney;CoS/Dep CoS/LD,Cong. Melissa Bean;Sr. LA,Cong. Baron Hill
Jason Van Pelt Legislative Director, Senior LA, LA, Staff Asst: Cong. Ed Whitfield
Katherine Dapper Staff Asst. Sen. Murray (D-WA)
Shay Hancock MLA Sen. Murray (D-WA), LA Rep Smith (D-WA)
Jason Gleason Chief of Staff/Legislative Director, Rep. John Sarbanes; Legislative Director/Legislative Asst/Legislative Correspondent/Staff Asst, Sen. Paul Sarbanes
Brittany Hernandez Senior Legislative Assistant, Legislative Assistant, Legislative Correspondent, Staff Assistant: Rep. Steve Cohen
Mathew Lapinski n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2021
Crossroads Strategies, LLC terminated an engagement in which they represented Alkermes, Inc. on Jan. 13, 2022.
Original Filing: 301322291.xml
Lobbying Issues
Advance the use of and access to FDA-approved medications to treat addiction and mental illness in criminal justice and public health settings; pharmaceutical supply chain issues; drug pricing.
Implementation of Comprehensive Addiction and Recovery Act of 2016 (P.L.114-198), 21st Century Cures Act (P.L.114-255), SUPPORT for Patients and Communities Act (P.L.115-271), and CARES Act (P.L.116-136).
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Drug Pricing; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Resolution (S.Con.Res.14)/Budget Reconciliation (H.R.5376).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings, including SAMHSA funding;
FY2022 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (H.R.4355/S.2604);
FY2022 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.4505);
FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502);
FY2022 Department of the Interior, Environment, and Related Agencies Appropriations Act (H.R.4372);
H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation;
FY2022 Consolidated Appropriations Act (H.R.4502).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2021
In Q3, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $50,000. The report was filed on Oct. 19, 2021.
Original Filing: 301306206.xml
Lobbying Issues
Advance the use of and access to FDA-approved medications to treat addiction and mental illness in criminal justice and public health settings; pharmaceutical supply chain issues; drug pricing.
Implementation of Comprehensive Addiction and Recovery Act of 2016 (P.L.114-198), 21st Century Cures Act (P.L.114-255), SUPPORT for Patients and Communities Act (P.L.115-271), and CARES Act (P.L.116-136).
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Drug Pricing; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Resolution (S.Con.Res.14)/Budget Reconciliation (H.R.5376).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings, including SAMHSA funding;
FY2022 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (H.R.4355/S.2604);
FY2022 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.4505);
FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502);
FY2022 Department of the Interior, Environment, and Related Agencies Appropriations Act (H.R.4372);
H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation;
FY2022 Consolidated Appropriations Act (H.R.4502).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2021
In Q2, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $50,000. The report was filed on July 18, 2021.
Original Filing: 301279086.xml
Lobbying Issues
Advance the use of and access to FDA-approved medications to treat addiction and mental illness in criminal justice and public health settings; pharmaceutical supply chain issues; drug pricing.
Implementation of Comprehensive Addiction and Recovery Act of 2016 (P.L.114-198), 21st Century Cures Act (P.L.114-255), SUPPORT for Patients and Communities Act (P.L.115-271), and CARES Act (P.L.116-136).
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Drug Pricing; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings, including SAMHSA funding;
FY2022 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act;
FY2022 Commerce, Justice, Science, and Related Agencies Appropriations Act;
FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act;
FY2022 Department of the Interior, Environment, and Related Agencies Appropriations Act;
H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2021
In Q1, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $50,000. The report was filed on April 19, 2021.
Original Filing: 301255788.xml
Lobbying Issues
Advance the use of and access to FDA-approved medications to treat addiction and mental illness in criminal justice and public health settings; pharmaceutical supply chain issues; drug pricing.
Implementation of Comprehensive Addiction and Recovery Act of 2016 (P.L.114-198), 21st Century Cures Act (P.L.114-255), SUPPORT for Patients and Communities Act (P.L.115-271), and CARES Act (P.L.116-136).
Executive Order on Access to Affordable Life-saving Medications (E.O.13937); Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O.13938); Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O.13939); Executive Orders on Lowering Drug Prices by Putting America First (E.O.13947, E.O.13948); Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O.13944); Executive Order on An America-First Healthcare Plan (E.O.13951).
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Drug Pricing; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings, including SAMHSA funding;
FY2022 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act;
FY2022 Commerce, Justice, Science, and Related Agencies Appropriations Act;
FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act;
FY2022 Department of the Interior, Environment, and Related Agencies Appropriations Act;
H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2020
In Q4, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $50,000. The report was filed on Jan. 20, 2021.
Original Filing: 301237601.xml
Lobbying Issues
Advance the use of and access to FDA-approved medications to treat addiction and mental illness in criminal justice and public health settings; pharmaceutical supply chain issues; drug pricing.
Implementation of Comprehensive Addiction and Recovery Act of 2016 (P.L.114-198), 21st Century Cures Act (P.L.114-255), SUPPORT for Patients and Communities Act (P.L.115-271), and CARES Act (P.L.116-136).
Executive Order on Access to Affordable Life-saving Medications (E.O. 13937).
Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O. 13938).
Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O. 13939).
Executive Orders on Lowering Drug Prices by Putting America First (E.O. 13947, E.O. 13948).
Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O. 13944).
Executive Order on An America-First Healthcare Plan (E.O. 13951).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program and drug pricing;
H.R.3, Lower Drug Costs Now Act of 2019; S.2543, Prescription Drug Pricing Reduction Act of 2019; H.R.19, Lower Costs, More Cures Act of 2019; H.R.1425, Patient Protection and Affordable Care Enhancement Act.
Medicaid issues associated with MAT; H.R.8337, Continuing Appropriations Act, 2021 and Other Extensions Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings, including SAMHSA funding;
FY2021 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (H.R.7609), FY2021 Consolidated Appropriations Act (H.R.7608);
FY2021 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.7667), FY2021 Consolidated Appropriations Act (H.R.7617);
FY2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.7614), FY2021 Consolidated Appropriations Act (H.R.7617);
H.R.748, CARES Act (P.L.116-136) implementation; H.R.6800, The Heroes Act; The HEALS Act; H.R.133, Making consolidated appropriations for the fiscal year ending September 30, 2021, providing coronavirus emergency response and relief, and for other purposes (P.L.116-260).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to prescription drug supply chains; H.R.6482/S.3537/S.3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020; H.R.6431, Made in America Emergency Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2020
In Q3, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $50,000. The report was filed on Oct. 17, 2020.
Original Filing: 301212635.xml
Lobbying Issues
Advance the use of and access to FDA-approved medications to treat addiction and mental illness in criminal justice and public health settings; pharmaceutical supply chain issues; drug pricing.
Implementation of Comprehensive Addiction and Recovery Act of 2016 (P.L.114-198), 21st Century Cures Act (P.L.114-255), SUPPORT for Patients and Communities Act (P.L.115-271), and CARES Act (P.L.116-136).
Executive Order on Access to Affordable Life-saving Medications (E.O. 13937).
Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O. 13938).
Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O. 13939).
Executive Orders on Lowering Drug Prices by Putting America First (E.O. 13947, E.O. 13948).
Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O. 13944).
Executive Order on An America-First Healthcare Plan (E.O. 13951).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program and drug pricing;
H.R.3, Lower Drug Costs Now Act of 2019; S.2543, Prescription Drug Pricing Reduction Act of 2019; H.R.19, Lower Costs, More Cures Act of 2019; H.R.1425, Patient Protection and Affordable Care Enhancement Act.
Medicaid issues associated with MAT; H.R.8337, Continuing Appropriations Act, 2021 and Other Extensions Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings, including SAMHSA funding;
FY2021 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (H.R.7609), FY2021 Consolidated Appropriations Act (H.R.7608);
FY2021 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.7667), FY2021 Consolidated Appropriations Act (H.R.7617);
FY2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.7614), FY2021 Consolidated Appropriations Act (H.R.7617);
H.R.748, CARES Act (P.L.116-136) implementation; H.R.6800, The Heroes Act; The HEALS Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to prescription drug supply chains; H.R.6482/S.3537/S.3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020; H.R.6431, Made in America Emergency Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2020
In Q2, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $50,000. The report was filed on July 18, 2020.
Original Filing: 301193444.xml
Lobbying Issues
Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings; confronting the opioid and mental illness epidemic including funding issues; pharmaceutical supply chain issues.
Implementation of Comprehensive Addiction and Recovery Act of 2016 (P.L.114-198).
Implementation of 21st Century Cures Act (P.L.114-255).
Implementation of SUPPORT for Patients and Communities Act (P.L.115-271).
H.R.748, CARES Act (P.L.116-136) implementation.
H.R.6482/S.3537/S.3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020.
H.R.6431, Made in America Emergency Preparedness Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program and drug pricing;
H.R.3, Lower Drug Costs Now Act of 2019;
S.2543, Prescription Drug Pricing Reduction Act of 2019;
H.R.19, Lower Costs, More Cures Act of 2019;
H.R.1425, State Health Care Premium Reduction Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Confronting the opioid and mental illness epidemic including funding issues;
FY 2021 Military Construction, Veterans Affairs, and Related Agencies Appropriations;
FY 2021 Commerce, Justice, Science, and Related Agencies Appropriations;
FY 2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $50,000. The report was filed on April 18, 2020.
Original Filing: 301172060.xml
Lobbying Issues
Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings.
Confronting the opioid and mental illness epidemic including funding issues.
Implementation of Comprehensive Addiction and Recovery Act of 2016 (P.L.114-198).
Implementation of 21st Century Cures Act (P.L.114-255).
Implementation of SUPPORT for Patients and Communities Act (P.L.115-271).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program and drug pricing;
H.R.3, Lower Drug Costs Now Act of 2019;
S.2543, Prescription Drug Pricing Reduction Act of 2019;
H.R.19, Lower Costs, More Cures Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Confronting the opioid and mental illness epidemic including funding issues;
FY 2021 Military Construction, Veterans Affairs, and Related Agencies Appropriations;
FY 2021 Commerce, Justice, Science, and Related Agencies Appropriations;
FY 2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $50,000. The report was filed on Jan. 19, 2020.
Original Filing: 301121603.xml
Lobbying Issues
Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings.
Confronting the opioid and mental illness epidemic including funding issues.
Implementation of Comprehensive Addiction and Recovery Act of 2016 (P.L.114-198).
Implementation of 21st Century Cures Act (P.L.114-255).
Implementation of SUPPORT for Patients and Communities Act (P.L.115-271).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare and Medicaid issues such as drug pricing;
H.R.3, Lower Drug Costs Now Act of 2019;
S.2543, Prescription Drug Pricing Reduction Act of 2019;
H.R.19, Lower Costs, More Cures Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Confronting the opioid and mental illness epidemic including funding issues;
H.R.3055/S.2584, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure;
H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and H.R.2740, the FY2020 Consolidated measure;
H.R.1158, Consolidated Appropriations Act, 2020 (P.L.116-93);
H.R.1865, Further Consolidated Appropriations Act, 2020 (P.L.116-94).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $50,000. The report was filed on Oct. 19, 2019.
Original Filing: 301072024.xml
Lobbying Issues
Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings.
Confronting the opioid and mental illness epidemic including funding issues.
Implementation of Comprehensive Addiction and Recovery Act of 2016 (P.L.114-198).
Implementation of 21st Century Cures Act (P.L.114-255).
Implementation of SUPPORT for Patients and Communities Act (P.L.115-271).
H.R.3055/S.2584, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure.
H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and H.R.2740, the FY2020 Consolidated measure.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare and Medicaid issues such as drug pricing.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $50,000. The report was filed on July 20, 2019.
Original Filing: 301052947.xml
Lobbying Issues
Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings.
Confronting the opioid and mental illness epidemic including funding issues.
Implementation of Comprehensive Addiction and Recovery Act of 2016 (P.L.114-198).
Implementation of 21st Century Cures Act (P.L.114-255).
Implementation of SUPPORT for Patients and Communities Act (P.L.115-271).
H.R.3055, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure.
H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and H.R.2740, the FY2020 Consolidated measure.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $50,000. The report was filed on April 21, 2019.
Original Filing: 301032864.xml
Lobbying Issues
Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings.
Confronting the opioid and mental illness epidemic including funding issues.
Implementation of Comprehensive Addiction and Recovery Act of 2016 (P.L.114-198).
Implementation of 21st Century Cures Act (P.L.114-255).
Implementation of SUPPORT for Patients and Communities Act (P.L.115-271).
H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6).
FY 2020 Commerce, Justice, Science, and Related Agencies Appropriations.
FY 2020 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $50,000. The report was filed on Jan. 19, 2019.
Original Filing: 301010731.xml
Lobbying Issues
Implementation of Comprehensive Addiction and Recovery Act of 2016 (P.L.114-198);
Implementation of 21st Century Cures Act (P.L.114-146);
Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings;
Confronting the opioid and mental illness epidemic including funding issues;
H.R.5327, Comprehensive Opioid Recovery Centers Act of 2018;
S.2680, Opioid Crisis Response Act of 2018;
H.R.6, SUPPORT for Patients and Communities Act (P.L.115-271);
H.R.5952/S.3072, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2019;
H.R.5895, Energy and Water, Legislative Branch, and Military Construction and Veterans Affairs Appropriations Act, 2019 (P.L.115-244);
H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $50,000. The report was filed on Oct. 19, 2018.
Original Filing: 300992110.xml
Lobbying Issues
Implementation of Comprehensive Addiction and Recovery Act of 2016 (P.L.114-198);
Implementation of 21st Century Cures Act (P.L.114-146);
Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings;
Confronting the opioid and mental illness epidemic including funding issues;
H.R.5327, Comprehensive Opioid Recovery Centers Act of 2018;
S.2680, Opioid Crisis Response Act of 2018;
H.R.6, SUPPORT for Patients and Communities Act;
S.3158/H.R.6470, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019;
H.R.5952/S.3072, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2019;
H.R.5786/S.3024, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2019;
H.R.5895, Energy and Water, Legislative Branch, and Military Construction and Veterans Affairs Appropriations Act, 2019 (P.L.115-244);
H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $60,000. The report was filed on July 19, 2018.
Original Filing: 300972508.xml
Lobbying Issues
Implementation of Comprehensive Addiction and Recovery Act of 2016 (P.L.114-198);
Implementation of 21st Century Cures Act (P.L.114-146);
Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings;
Confronting the opioid and mental illness epidemic including funding issues;
H.R.5327, Comprehensive Opioid Recovery Centers Act of 2018;
S.2680, Opioid Crisis Response Act of 2018;
H.R.6, SUPPORT for Patients and Communities Act;
S.3158/House Draft, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019;
H.R.5952/S.3072, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2019;
H.R.5786/S.3024, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2019.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $60,000. The report was filed on April 20, 2018.
Original Filing: 300952891.xml
Lobbying Issues
Implementation of Comprehensive Addiction and Recovery Act of 2016 (P.L.114-198);
Implementation of 21st Century Cures Act (P.L.114-146);
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017;
Confronting the opioid and mental illness epidemic.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings;
Opioid funding issues;
Discussion draft of Comprehensive Opioid Recovery Centers Act;
H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018;
H.R.3267/S.1662, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2018;
H.R.2998/S.1557, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2018;
H.R.1370, Further Additional Continuing Appropriations Act, 2018 (P.L.115-96);
H.R.1892, Bipartisan Budget Act of 2018 (P.L.115-123);
H.R.1625, Consolidated Appropriations Act, 2018 (P.L.115-141);
FY19 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations;
FY19 Commerce, Justice, Science, and Related Agencies Appropriations;
FY19 Military Construction, Veterans Affairs, and Related Agencies Appropriations.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $60,000. The report was filed on Jan. 20, 2018.
Original Filing: 300931735.xml
Lobbying Issues
Implementation of P.L.114-198, Comprehensive Addiction and Recovery Act of 2016;
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017;
Confronting the opioid and mental illness epidemic.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018;
H.R.3267/S.1662, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2018;
H.R.2998/S.1557, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2018;
H.J.Res.123, Making further continuing appropriations for fiscal year 2018, and for other purposes (P.L.115-90);
H.J.Res.124, Making further additional continuing appropriations for fiscal year 2018, and for other purposes;
H.R.1370, Further Additional Continuing Appropriations Act, 2018 (P.L.115-96);
Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.1, Tax Cuts and Jobs Act (P.L.115-97); issues related to tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $60,000. The report was filed on Oct. 19, 2017.
Original Filing: 300908003.xml
Lobbying Issues
Implementation of P.L.114-198, Comprehensive Addiction and Recovery Act of 2016;
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017;
H.R.2430/S.934, FDA Reauthorization Act of 2017 (P.L.115-52);
confronting the opioid and mental illness epidemic.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018; H.R.3267/S.1662, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2018; H.R.2998/S.1557, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2018; H.R.3354, Make America Secure and Prosperous Appropriations Act, 2018; advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $60,000. The report was filed on July 20, 2017.
Original Filing: 300891839.xml
Lobbying Issues
Implementation of P.L.114-198, Comprehensive Addiction and Recovery Act of 2016; confronting the opioid and mental illness epidemic.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2018, Commerce, Justice, Science, and Related Agencies Appropriations; FY2018, Military Construction, Veterans Affairs, and Related Agencies Appropriations; H.R.244, Consolidated Appropriations Act 2017 (P.L.115-31); advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $60,000. The report was filed on April 19, 2017.
Original Filing: 300869478.xml
Lobbying Issues
Implementation of P.L.114-198, Comprehensive Addiction and Recovery Act of 2016; confronting the opioid and mental illness epidemic.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2017/FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2017/FY2018, Commerce, Justice, Science, and Related Agencies Appropriations; FY2017/FY2018, Military Construction, Veterans Affairs, and Related Agencies Appropriations; advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $60,000. The report was filed on Jan. 17, 2017.
Original Filing: 300847962.xml
Lobbying Issues
Implementation of P.L.114-198, Comprehensive Addiction and Recovery Act of 2016; H.R.34, 21st Century Cures Act (P.L.114-255); confronting the opioid and mental illness epidemic.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S.3040/H.R.5926, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017; H.R.5393/S.2837, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2017; H.R.2577/H.R.4974/S.2806, Military Construction and Veterans Affairs and Related Agencies Appropriations Act, 2017; H.R.2028, Further Continuing and Security Assistance Appropriations Act, 2017 (P.L.114-254); advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $60,000. The report was filed on Oct. 18, 2016.
Original Filing: 300831196.xml
Lobbying Issues
H.R.2872, Opioid Addiction and Modernization Act; P.L.114-198, Comprehensive Addiction and Recovery Act of 2016; S.1455, Recovery Enhancement for Addiction Treatment Act (TREAT Act); S.2256, Co-Prescribing Saves Lives Act of 2015; H.R.4981, Opioid Use Disorder Treatment Expansion and Modernization Act; confronting the opioid and mental illness epidemic.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S.3040/H.R.5926, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017; H.R.5393/S.2837, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2017; H.R.2577/H.R.4974/S.2806, Military Construction and Veterans Affairs and Related Agencies Appropriations Act, 2017; advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $60,000. The report was filed on July 19, 2016.
Original Filing: 300815729.xml
Lobbying Issues
H.R.2872, Opioid Addiction and Modernization Act; S.524, Comprehensive Addiction and Recovery Act of 2016; S.1455, Recovery Enhancement for Addiction Treatment Act (TREAT Act); S.2256, Co-Prescribing Saves Lives Act of 2015; H.R.4981, Opioid Use Disorder Treatment Expansion and Modernization Act; confronting the opioid and mental illness epidemic.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S.3040/House Committee Draft, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017; H.R.5393/S.2837, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2017; H.R.2577/H.R.4974/S.2806, Military Construction and Veterans Affairs and Related Agencies Appropriations Act, 2017; advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $60,000. The report was filed on April 19, 2016.
Original Filing: 300795393.xml
Lobbying Issues
H.R.2872, Opioid Addiction and Modernization Act; S.524, Comprehensive Addiction and Recovery Act of 2016; S.1455, Recovery Enhancement for Addiction Treatment Act (TREAT Act); S.2256, Co-Prescribing Saves Lives Act of 2015; confronting the opioid and mental illness epidemic.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2017 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2017 Commerce, Justice, Science, and Related Agencies Appropriations; FY2017 Military Construction, Veterans Affairs, and Related Agencies Appropriations; H.Con.Res.125, Establishing the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026; advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Crossroads Strategies, LLC lobbied for Alkermes, Inc. , earning $60,000. The report was filed on Jan. 19, 2016.
Original Filing: 300775442.xml
Lobbying Issues
H.R.2872, Opioid Addiction and Modernization Act; confronting the opioid and mental illness epidemic.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S.1695/H.R.3020, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016 and Senate/H.R.2578, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2016; P.L.114-74, Bipartisan Budget Act of 2015; P.L.114-113, Consolidated Appropriations Act, 2016; advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
Crossroads Strategies, LLC filed a lobbying registration on Nov. 5, 2015 to represent Alkermes, Inc., effective Oct. 8, 2015.
Original Filing: 300767299.xml
Issue(s) they said they’d lobby about: H.R.2872, Opioid Addiction and Modernization Act; confronting the opioid and mental illness epidemic. S.1695/H.R.3020, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016 and Senate/H.R.2578, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2016; advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...